Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Publication | Closed Access

DOI

Citations

References

2014

Year

Joachim von Pawel, Jimmie H. Harvey, David R. Spigel, Mircea Dediu, Martin Reck, C. Cebotaru, Robin Humphreys, Matthew Gribbin, Norma Lynn Fox, D. Ross Camidge

Clinical Lung Cancer

Phase Ii TrialMedicineImmunologyCell DeathImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung Cancer